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Kajian Penilaian Kualiti Mempreskripsi oleh Pengamal Perubatan Primer 
Universiti Sains Malaysia dan Penilaian Impak Menggunakan Model Andersen 
dan Kaedah Skor Kecenderungan 
 
 
ABSTRAK 
 
Peningkatan kos penjagaan kesihatan adalah masalah di seluruh dunia. 
Menilai dan memperbaiki kualiti sepatutnya menjadi salah satu agenda reformasi dan 
kawalan kos perkhidmatan penjagaan kesihatan. Mempreskripsi ubat adalah salah 
satu perkhidmatan penjagaan kesihatan yang memerlukan penilaian dan 
penambahbaikan secara berterusan. Namun, kaedah yang sedia ada untuk menilai 
kesesuaian pempreskripsian menghadapi banyak kekurangan termasuklah daripada 
segi kesahan ramalan. Kajian ini menilai corak pempreskripsian oleh penyedia 
penjagaan kesihatan asas di Universiti Sains Malaysia (USM). USM menawarkan 
khidmat penjagaan kesihatan asas kepada benefisiarinya. Penilaian telah dilakukan 
pada peringkat makro di mana teras petunjuk pempreskripsian dan metodologi dos 
harian yang tetap (DDD) yang telah digunapakai oleh Pertubuhan Kesihatan Sedunia 
(WHO) dikira daripada data akademik tahunan pengguna perkhidmatan ini. Penilaian 
juga telah dilakukan pada peringkat mikro (pesakit) di mana masalah berkaitan drug 
(DRP) berhubung dengan keselamatan pempreskripsian telah dikenalpasti di dalam 
setiap preskripsi yang dikeluarkan dalam dua tahun akademik. Kenyataan yang 
mewakili kejadian DRP telah dibangun dan disahkan. Setiap kenyataan adalah 
senario klinikal di mana drug telah dipreskripsi tetapi perakuan sumber informasi 
daripada pihak berkuasa drug adalah bertentangan dengan preskripsi tersebut. 
Berdasarkan model penggunaan penjagaan kesihatan Anderson, satu rangka kerja 
 
 
 
xxii
 
 
 
 
telah dibangunkan untuk menilai kesan pendedahan pesakit terhadap DRP dan 
kaitannya dengan bilangan lawatan penjagaan asas. Analisis komponen regresi 
digunakan untuk menilai kesan ini. Komponen status kesihatan daripada model 
Anderson telah dianggarkan daripada beberapa jenis drug yang diambil oleh pesakit. 
Bagi mengkaji hubungan kesan- akibat di antara pendedahan dan peningkatan 
bilangan lawatan, teknik statistik skor kecenderungan (PS) telah digunakan selepas 
percubaan dan anggaran yang sesuai dilakukan. Memandangkan bahawa majoriti 
benefisiari USM adalah muda dan sihat, penilaian peringkat makro menunjukkan 
adanya isu-isu berpotensi dalam pempreskripsian drug berbanding corak yang 
dijangkakan. Tambahan pula, prevalens DRP adalah tinggi dengan beberapa 
kumpulan drug terutamanya antihistamin dan drug gastrousus. Analisis regresi 
menunjukkan bahawa pendedahan pesakit kepada DRP mempunyai kesan 
ketidakbergantungan yang positif kepada peningkatan dalam lawatan penjagaan 
kesihatan asas selepas mengawal kovariat, termasuk status kesihatan.. Sifat yang 
menyebabkan kesan ini telah disahkan di dalam analisis PS di mana pesakit yang 
terdedah mempunyai jumlah purata 6.5 kali lawatan berbanding dengan kawalan. 
Kesimpulannya, kajian ini telah membuktikan bahawa adanya isu-isu yang 
berpotensi di dalam pempreskripsian drug. Pendedahan kepada DRP telah 
dihubungkan kepada penggunaan penjagaan kesihatan yang tinggi. Intervensi juga 
adalah perlu untuk mengelakkan potensi berlakunya morbiditi berkaitan drug dan 
bagi mengurangkan kos penjagaan kesihatan. 
 
 
 
xxiii
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MALAYSIA’S PRIMARY CARE PROVIDERS AND EVALUATION OF ITS 
IMPACT USING ANDERSEN’S MODEL AND  
PROPENSITY SCORE METHOD 
 
 
ABSTRACT 
 
Escalation of healthcare cost is a world-wide problem. Assessing and 
improving the quality of healthcare services should be a part of any agenda for 
healthcare reforms and cost containment. Drug prescribing is one of healthcare 
services that requires continuous assessment and improvement. However, available 
tools for assessing prescribing appropriateness have many shortcomings including 
lack of predictive validity. This study evaluates the prescribing pattern of Universiti 
Sains Malaysia’s (USM’s) primary healthcare providers. USM offers primary 
healthcare services to its beneficiaries. The evaluation was performed at a macro 
level where the core prescribing indicators and the defined daily dose (DDD) 
methodologies adopted by the World Health Organization (WHO) were calculated 
from an academic year data of service users. Evaluation was also performed at a 
micro level (the patient) where drug-related problems (DRP) pertaining to the safety 
of prescribing were identified in each drug prescription issued within two academic 
years. Statements representing DRP event were developed and validated. Each 
statement is a clinical scenario in which a drug was prescribed while the authoritative 
drug information sources recommend against its prescribing. Based on Andersen’s  
healthcare utilization model, a framework was developed to evaluate the effect of 
patient’s exposure to DRPs on the number of primary care visits. Regression analysis 
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was used to evaluate this effect. The health status component of Andersen’s model 
was estimated from some of the drugs used by the patients. To study the cause-effect 
relationship between exposure and increment in number of visits, the propensity 
score (PS) statistical technique was applied after proper estimation and testing. In 
view of the fact that the majority of USM’s beneficiaries are in young and healthy 
ages, the macro level evaluation has shown potential issues in drug prescribing 
compared to the expected pattern. Moreover, the prevalence of DRP was high with 
some drug groups especially antihistamines and gastrointestinal drugs. Regression 
analysis has shown that the exposure of patients to DRPs has an independent positive 
effect on the increase in primary care visits after controlling for other covariates, 
including the health status. The causal nature of this effect was confirmed in the PS 
analyses where the exposed patients had, on average, 6.5 visits more than their 
controls. In conclusion, the study has documented potential issues in drug 
prescribing. Exposure to DRPs was linked to higher utilization of healthcare. 
Intervention is warranted to prevent the potential drug-related morbidities and to 
decrease healthcare cost. 
 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Thesis Overview 
This thesis consists of four parts. Part One is a classical study that 
investigated drug prescribing in clinics that offer primary healthcare services to 
beneficiaries of Universiti Sains Malaysia (USM). The data of part one, as well as 
that of the other parts, were obtained from USM computerized databases which keep 
electronic medical records (EMR) of patients. The defined daily dose (DDD) and the 
WHO core prescribing indicators were used in this part. These tools assess drug 
prescribing generally from aggregated data without the requirements of clinical 
details of the patients. Despite this, they can provide an overview on the situation. 
They can flag potential problems in drug prescribing that require further 
investigations. The findings of part one can serve as a baseline to which future 
prescribing patterns in these clinics can be compared from time to time or after any 
policy implementation. Results of part one showed potential issues in drug 
prescribing. The next step was to investigate whether these issues have an economic 
impact such as increasing the number of visits of patients to those clinics. This 
impact was studied using Andersen’s model of healthcare utilization.  
Andersen’s model uses the patient as the unit of analysis, and conceptualizes 
healthcare utilization as a function of predisposing factors, enabling factors and 
needs factors of the patient. It also implicates healthcare quality as a determinant of 
healthcare use. While the predisposing factors and enabling factors are readily 
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available in the data, and the number of primary care visits of patients could be easily 
calculated, the needs factors and the quality of care required preparatory work before 
the model could be used. These two tasks were performed in the second part and the 
third part, respectively. 
Part Two of this thesis deals with developing and validating an estimate of 
the needs factors of patients, the third input in the model. This estimate is called the 
long-term therapeutic group index (LTTGI). It is the number of therapeutic groups 
the patient uses, whereby these groups are used to treat disease conditions that take 
long time to cure or are not curable or go through exacerbation and remission or need 
continuous treatment or need repeated treatment courses. A panel of clinical 
pharmacists validated the use of these groups in such disease conditions. 
Part Three assesses quality of prescribing using Donabedian’s framework of 
healthcare quality assessment, focusing on the process component of quality. 
Specifically, prescribing appropriateness (at the patient level) was assessed. Hepler 
and Strand framework of drug-related morbidity (DRM) and drug-related problems 
(DRPs) states that: for a DRM to be  preventable, it must be preceded by a 
recognizable and controllable DRP. In part three, statements on five categories of 
DRPs were developed and validated. These categories are overprescribing, allergenic 
prescription, drug interaction, contraindication, and pharmacologic duplication. 
Then, patients’ EMR were screened for each of these statements. Finally, the DRP 
events scored-up for each patient. This score was incorporated into Andersen’s 
model to represent prescribing quality. 
At this stage, the components of Andersen’s model has been made available. 
The relationship between exposure to these DRP categories and patients’ visits was 
assessed within the model. 
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Part Four attempts to establish a cause-effect relationship between exposure 
to DRPs and increased healthcare utilization. That was achieved by applying the 
propensity score (PS) analyses. PS  was estimated for each patient based on the 
number of DRP exposures. PS was then used to form matched pairs of patients 
whereby the two patients constituting any pair are closest in their PS values but 
farthest in their number of exposure to DRPs. Next, the pairs were dissociated into 
two groups; the exposed and the unexposed groups. Finally, the two groups were 
compared in the number of visits. 
 
1.2 Background 
Drug prescribing is probably the most common medical strategy in treating 
and preventing diseases affecting human beings. In a recent US’ national ambulatory 
medical care survey (Cherry et al., 2008), drugs were prescribed in 70% of 
physician’s office visits. On average, 2.1 drugs were prescribed per visit.  
New diseases are continually being discovered and new drugs are being 
invented and introduced into the pharmaceutical market. Randomized controlled 
trials propose benefits of new drugs and support potential new values of the already 
existing drugs for new medical indications.  
Drug benefits have extended from treating and managing diseases to 
controlling the risk factors behind diseases. As examples, statin anti-hyperlipidemic 
drugs and aspirin are used for primary prevention of coronary heart disease, and 
aspirin and warfarin are used in primary prevention of ischemic stroke.     
Furthermore, public access to healthcare and the availability of drugs is 
improving due to collaborations of countries and organizations. Elderly population 
present larger proportion of any community than any time before. All these factors 
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contribute to increasing drug prescribing and drug use among populations across the 
globe.  
The quality of drugs in the pharmaceutical markets is better than any time 
before. Good manufacturing practice (GMP) is a pre-requisite to drug marketing in 
most countries. In addition, studies of bioequivalence on generic drug products are 
being implemented in developed countries and some of the developing countries as 
well. These regulations on marketing drugs have increased the confidence in both 
healthcare professionals and the general public that the marketed drugs have the 
capacity to effectively fight diseases. 
The beneficial effects of drugs have been continuously shown, but drugs are 
not free of danger. A drug is double-edged sword. Parallel to the increase in drug 
use, numerous studies have shown that inappropriate use of drugs has led to an 
increase in adverse drug reactions and adverse drug events.  
In the literature of patient-centered approach and pharmaceutical care, these 
adverse outcomes of drug use are referred to as drug-related morbidities (DRMs). A 
DRM is defined as “clinical or bio-social manifestation of unresolved drug-related 
problems.” (Hepler and Segal, 2003). A drug-related problem (DRP), in turn, is 
defined as “an event or a circumstance involving drug treatment that actually or 
potentially interferes with patient’s achievement of an optimum outcome of medical 
care” (Strand et al., 1990). Eight categories of DRPs were identified. These 
categories are untreated indications, improper drug selection, sub-therapeutic dose, 
failure to receive drug, overdose, adverse drug reaction, drug interactions, and drug 
use without indication. 
Drug-related problems are a worldwide concern. They cause morbidity and 
mortality (Ebbesen et al., 2001, Buajordet et al., 2001),  increase rate of 
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hospitalization and hospitalization days (Roughead et al., 1998, Kongkaew et al., 
2008, van der Hooft et al., 2008, van der Hooft et al., 2006), increase frequency of 
emergency visits (Yee et al., 2005), increase primary care utilization and cost 
(Guerreiro et al., 2005, Ernst and Grizzle, 2001, Johnson and Bootman, 1995), and 
lea to an overall increase in healthcare expenditure  (Forster et al., 2003, Gandhi et 
al., 2003, Silverman et al., 2003).  
The magnitude of DRPs is so immense that it needs to be addressed. Though 
the elderly are the population most studied, the prevalence of DRPs is not low in the 
younger age groups. They involve all levels of healthcare. In residence homes of 
elderly in the US, large number of studies have found high prevalence of DRP (Lau 
et al., 2004, Lau et al., 2005). The situation in primary care is no better. Two studies 
in the US general practice and in community pharmacies of some European countries 
reported DRP prevalence as high as 61% and 64%, respectively (Paulino et al., 2004, 
Strand et al., 2004). A recent study in Spanish primary care of elderly reported a 
DRP prevalence of 46% (Gomez et al., 2009). A study compared DRPs in primary 
care in Minnesota and Australia reported prevalence of 70% and 90%, respectively 
(Rao et al., 2007).  
1.2.1 Safety Issues in Drug Use 
Following the release of the Institute of Medicine (IOM) report entitled “To 
Err Is Human: Building a Safer Health System” (Kohn LT, 1999), numerous efforts 
have been directed to ensure quality and safe health care systems. The report 
estimated an occurrence of  44000-98000 deaths in American inpatient care facilities 
each year due to medical errors; the share of medication errors were 7000 deaths. 
These findings put medical errors among the leading causes of mortality and one of 
the high cost diseases (Kohn LT, 1999). Since then, IOM has started series of 
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publications called “Quality chasm” which aim to improve the quality and safety of 
healthcare systems. The IOM framework categorizes health care quality into safety, 
effectiveness, patient-centeredness, timeliness, efficiency, and equity (Berwick, 
2002, Institute of Medicine (U.S.). Committee on Quality of Health Care in 
America., 2001). Issues related to drug  safety is one of the concerns in IOM quality 
chasm series (Aspden and Institute of Medicine (U.S.). Committee on Identifying 
and Preventing Medication Errors., 2007). 
Similar efforts have been initiated in Europe. In the United Kingdom (UK), 
for example, the Department of Health has identified the needs to address medical 
errors (Donaldson, 2002). The focus of the UK’s government on quality 
improvement has resulted in the establishment of authorities such as the National 
Institute for Clinical Excellence (NICE) and the national performance framework. 
The purpose of these authorities is to measure and improve the quality in different 
areas of healthcare. Furthermore, and in relation to general practice specifically, 
Prescribing Analysis and Cost (PACT) database was established. PACT database 
allows the general practitioners to review their own prescribing and to compare with 
their peers. It is also used in research aiming to improve the quality of prescribing in 
general practice in the UK. 
 
1.3 Overview on Healthcare Scheme of Universiti Sains Malaysia  
Apart from hospital services offered by the Malaysian government for its 
population, Universiti Sains Malaysia (USM) offers primary healthcare services to its 
beneficiaries through its Health Center (USMHC) located at the main university 
campus in Penangand through a panel of private clinics (USMPC) and pharmacies. 
USM beneficiaries are staff of USM, their spouses and children as well as USM’s 
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students, their spouses and children. All beneficiaries have equal access to the 
healthcare services in USMHC. However, their access to the USMPC is not the 
same; staff and their dependants have unlimited access while students have limited 
access of 6 visits per year and student’s dependants and pensioners do not have 
access to USMPC. 
USMHC is owned by USM, and the healthcare providers are employees of 
USM. Panel clinics are private entities and are reimbursed by USM on the bases of 
fee-for-service (FFS). This FFS is capped to a ceiling according to the service 
provided. For consultation-only visits, USM reimburses USMPC with RM9. If an 
antibiotic has been prescribed, the reimbursement is RM14. If drugs other than 
antibiotics have been prescribed, the reimbursement becomes RM12.  
While dispensing takes place in the pharmacy unit of the USMHC, most 
prescriptions issued by USMPC are dispensed by the respective clinics, since the 
Malaysian regulations allow private clinics to dispense prescriptions. However, if the 
patient chooses to obtain the prescribed medications from a pharmacy outside the 
clinic, dispensing will take place in one of the USM’s panel pharmacies. Pharmacies 
send claims to USM, which then reimburses them for the prescriptions they 
dispensed. 
 
1.4 Problem Statement 
Escalation of healthcare cost is a worldwide problem. Any healthcare reforms 
aim to decrease the cost of healthcare. Healthcare escalation is multifactorial 
regardless of the context and healthcare system characteristics. However, many 
factors contributing to the cost escalation are controllable. Identifying these factors, 
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their causes, and the magnitude of their contribution in cost escalation is important in 
order to formulate relevant interventions towards cost containments. 
Delivering quality healthcare is one of the means for cost containment. The 
need for quality assessment and improvement in healthcare is indisputable. Of 
healthcare services that need continuous quality assessment and improvement is drug 
prescribing.  
Often, people benefit from drug therapy, but the potential of adverse 
outcomes are always present. These potential adverse outcomes range from minor 
adverse drug events to fatality. Research has shown that the cost of drug-related 
morbidities (DRM) and mortalities exceeds the cost of the drugs themselves 
(Guerreiro et al., 2005, Ernst and Grizzle, 2001, Johnson and Bootman, 1995). 
Adverse outcomes of drug therapy are costly; fortunately, most of them are 
preventable. Assuring safe and effective prescribing practice should be a priority in 
any quality improvement program. 
 Methods that assess the outcomes of exposure to drug-related problems 
(DRPs) require data-rich environment such as those in the hospital setting. In 
primary care setting, on the contrary, data on outcomes are often lacking. In such 
cases, assessing the quality of drug prescribing by assessing the prescribing pattern is 
more reliable. Assessing the prescribing pattern aims to identify DRPs in drug 
prescribing.   
The validity of prescribing assessment methods relies on the strength of the 
link between the DRPs in the prescribing step of drug use and the drug therapy 
adverse outcomes  (known as drug-related morbidity, DRM). The evidence that links 
safety-related prescribing assessment methods is not scientifically sound. Most 
assessment tools were developed through consensus-based approaches, and are 
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limited to elderly population. Even in cases of sound scientific evidence, 
operationalizing the assessment is hindered by data unavailability.   
As stated earlier, the drug use in primary care is still far from being a system 
as conceptualized by pharmaceutical care philosophy. Drug use in primary care is a 
process with the inherent lack of the feedback loop (the monitoring step) that helps in 
detecting, resolving, and preventing DRPs. This affects both the effectiveness and 
the safety aspects of drug therapy. However, safety comes first, particularly in this 
instance. That is because effectiveness is always in the provider’s mind and can be 
checked easily in the subsequent encounters by observing the signs and the 
symptoms of the disease being treated. Safety-related DRPs, on the other hand, has a 
relatively higher potential to go unrecognized. The result is events of DRM with 
consequent non-compliance, which definitely will adversely affect drug 
effectiveness. Furthermore, and in relation to the lack of monitoring step, safety-
related DRP need to be defined more strictly, to allow the prescriber to judge the 
benefit and the risk of the majority of the prescriptions. Safety-related DRPs should 
be restricted to those prescribing events in which the potential risk of prescribing a 
drug outweighs any potential benefit from prescribing that drug. 
 Attempts to use indicators of inappropriate prescribing as quality assessment 
tool are devalued by the lack of predictive validity. That is, if the high prevalence of 
inappropriate prescribing reflects low quality, it is anticipated that it will result in 
negative healthcare outcomes (mortality, morbidity) and higher healthcare cost and 
utilization. However, the results of studies investigating this relationship are 
conflicting (Lin et al., 2008, Jano and Aparasu, 2007, Fillenbaum et al., 2004, Donna 
Marie Fick et al., 2001). So, the questions are: do these indicators measure a wrong 
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thing? Or is it because of issues related to study designs, data validity, and data 
availability?  
Exposure to DRPs is supposed to increase healthcare utilization of those who 
are exposed. Few studies have investigated this economic effect. Even, those studies 
did not investigate the causal nature of the effect. Ethically, no randomized 
experimental study can be carried out to investigate the causal effect of inappropriate 
prescribing on healthcare utilization. 
The previously-mentioned issues were avoided in this thesis. This thesis has 
developed statements that assess the safety of prescribing in primary care practice. 
The statements were constructed from authoritative textbooks of therapeutics and 
drug information; these sources enhance the validity of the statements. This thesis 
has considered only prescribing events in which the risk of prescribing a drug  
outweighs any potential benefit. These statements were then validated by a panel of 
clinical pharmacists. The economic effect of exposure was assessed using 
Andersen’s model of healthcare utilization. In relation to cause-effect relationship 
between the exposure and the healthcare utilization, this thesis used propensity score 
approach to study the causality in this relationship. 
To the best of the researcher’s knowledge, this is the first work to address 
measuring the causal effect of exposure to safety-related DRPs in the prescribing 
step of drug use on primary healthcare utilization by applying the propensity score. 
 
1.5 Research Hypothesis 
This study hypothesizes that exposure to DRPs in the the prescribing step of 
drug use leads to increase in healthcare utilization and cost. Such exposure causes 
harm to the exposed individuals. The harm may not be severe enough to lead to 
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emergency visit or hospitalization. However, it can be so annoying that the 
individuals will seek medical attention at primary care clinics. As a result, the 
exposed individuals will visit the primary care providers more frequently than their 
unexposed counterparts. That is to say, the exposure is a cause to an intermediate end 
(the annoying effect of exposure) which in turn is an intermediate cause to an 
ultimate end (the increase in the healthcare utilization, the number of visits and 
subsequently the cost). 
Gandhi et al. (2000) found that most of the detected DRM events were 
neither life threatening nor led to hospitalization; and such DRMs are minor to the 
providers but not to the patients. Those authors commented that prescribers often 
overlook such DRM despite the fact that they annoy the patients, hence causing 
dissatisfaction and increase in primary health service utilization. Most of these 
“minor” DRM were preventable (PDRMs). 
 
1.6 Study Objectives 
1.6.1 General Aims 
There are two primary aims to this thesis. The first is to assess the quality of 
prescribing of USM’s primary care providers. The second is to evaluate the 
relationship between the quality of prescribing and primary care utilization. 
1.6.2 Specific Objectives 
1) To assess the quality of prescribing at a macro level (USM’s Health 
Centre and USM’s panel clinics) from the aggregates of prescribing data. 
This objective has been achieved by: 
a) Calculating the defined daily dose (DDD) rates. 
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b) Calculating the WHO core prescribing indicators.  
2) Assessing the quality of prescribing at a micro level (the patient). This has 
been achieved by: 
a) Calculating the number of visits of each patient. 
b) Identifying socio-demographic factors of the patients. 
c) Estimating healthcare-related needs and health status of patients. 
d) Including this estimate in the Andersen’s model of healthcare 
utilization in which the number of visits represent the utilization 
variable. 
e) Validating the inclusion of this estimate in the model. 
f) Identifying the number of times each patient has been exposed to 
the following drug-related problem categories:  
i. Drug Over-prescription 
ii. Drug-Drug Interaction 
iii. Drug Contraindication 
iv. Allergenic Drug Prescription 
v. Pharmacologic Duplication 
3) Studying the prevalence of and the exposure rate to these DRP categories. 
4) Identifying the drugs and drug classes in these DRP categories. 
5) Studying the relationship between the number of exposures to DRPs  and 
the number of primary care visits of patients. 
6) Studying the causal effect of exposure to DRPs on the number of primary 
care visits of patients using propensity score analyses. These analyses 
included the following steps:    
a) Estimating the propensity score of exposure to DRPs. 
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b) Checking the estimated propensity score as a balancing score. 
c) Producing matched groups of patients based on propensity score and 
the number of exposures to DRPs. 
d) Comparing the number of visits between the two matched groups. 
 
1.7 Rationale of the Study 
There are concerns about the increase of healthcare cost and utilization in 
USM. To date, and to the best of the researcher’s knowledge, no study has been 
performed to relate drug use problems to the cost and utilization. This study 
investigates the contribution of problems in drug use to the utilization of USM 
healthcare. 
 
1.8 Significance of the Study 
This study extends the finding of drug over-utilization (based on part1: drug 
utilization study) from a crude measure of utilization to the effect of utilization on 
the patient’s overall health service utilization. In other word, this study uncovers 
some areas of expenditure related to drug use problems apart from the direct cost of 
drug over-utilization. 
The contributions of this thesis are: 
1) It describes drug prescribing pattern of USM’s Health Centre and USM’s 
panel clinics. These information can be used as a baseline against which 
comparisons can be made in the future; for example, after policy 
interventions related to drug prescribing. 
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2) It provides validated lists of some potential DRPs that occur in the 
prescribing step of drug use in the primary care. These lists have the 
potential to be used for the assessment of prescribing quality in the 
primary care setting.  
3) It provides information on the prevalence of the above-mentioned DRPs 
in the USM’s primary care system that offers healthcare to USM’s 
beneficiaries. 
4) It develops and validates a tool that estimates the health-related needs of 
individuals. This tool can be used to as an estimate of the health status of 
individuals in risk adjustment models of primary care utilization. 
5) It tests the assumptions of the Andersen’s model that the quality of 
healthcare provided has an effect on the healthcare utilization, as 
proposed by Andersen. It does so by applying the model with the 
incorporation of the exposure to DRPs as one of the determinants of the 
utilization. 
6) It evaluated the causality of exposure to DRPs on the increased utilization 
of the exposed individuals. 
 
1.9 The Scope of the Study 
This thesis deals with evaluating the quality of prescribing in primary care. 
The quality of prescribing in this thesis refers to its technical meaning. As mentioned 
above, quality in medical care has a technical part as well as an artistic part. The 
artistic part of prescribing quality is not measured in this thesis. The study by Britten 
and colleagues suggested a tool for assessing the art component, and to some extent 
the technical component, of prescribing appropriateness (Britten et al., 2003). That 
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study incorporated, by qualitative methods, the patient’s perspectives into assessing 
the prescribing appropriateness. 
In this thesis, drug prescribing was assessed at two levels. The first level was 
a macro-level. This macro-level assessment was gross in that it used the aggregate 
data on drug prescribing. Two well known tools were used in this assessment, the 
defined daily dose (DDD) and the WHO Core Prescribing Indicators. These two 
tools are more towards measuring rational drug prescribing than assessing the 
appropriateness of drug prescribing. Despite the grossness nature of this assessment 
using these two tools, potential issues in drug use can be highlighted in a timely and 
an inexpensive manner. They can highlight potential issues in drug prescribing that 
warrant further and deeper investigations.   
The second prescribing assessment performed in this thesis was at a micro-
level. It assessed the drug prescribing in relation to the patients for whom the drugs 
were prescribed. Unlike the DDD and the WHO indicators, the assessment at the 
micro-level targeted the appropriateness of drug prescribing in relation to patients’ 
clinical data. This assessment of prescribing appropriateness relied on explicit 
statements. Each statement refers to an event in the prescribing step of drug use 
where such prescribing should not have occurred. Most of these statements are 
related to the safety of drug prescribing.  
CHAPTER TWO 
LITERATURE REVIEW 
2.1 Chapter Overview 
This chapter contains many sections. The main aim of this chapter is 
reviewing the literature regarding the quality assessment in medical care, especially 
the quality of drug prescribing. The first section (2.2) of this chapter deals with the 
concept of quality in medical care. It includes the methods and the procedures used 
in assessing the quality of medical care. The second section (2.3) concentrates on 
assessing the quality of drug prescribing. This second section includes extensive 
literature review of the tools that are widely used to assess prescribing 
appropriateness.  
Three other topics are presented in brief at the end of this chapter. The third 
section (2.4) discusses the role of data availability in quality assessment. It focuses 
on how the dearth of data in primary care can be a barrier to the assessment of 
prescribing appropriateness. The fourth section (2.5) is a brief introduction to 
healthcare utilization models with special focus on the Andersen’s model. 
Andersen’s model is relevant because it is the conceptual framework adopted in this 
thesis. The last section (2.6) is about the propensity score. Propensity score is the 
statistical technique used in this thesis. The aim of its use was to analyze the causal 
nature of the effect of exposure to inappropriate prescribing on primary healthcare 
utilization. 
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2.2 Quality in Medical Care 
Avedis Donabedian is among the first pioneers who called for the need to 
assess and improve the quality in healthcare (Donabedian, 1978). Along with 
Donabedian’s framework of quality assessment in healthcare, IOM defines quality as 
“the degree to which health services for individuals and populations increase the 
likelihood of desired health outcomes and are consistent with current professional 
knowledge” (Institute of Medicine (U.S.). Committee on Quality of Health Care in 
America., 1990). The “Current professional knowledge” in the above-mentioned 
definition refers to the ever-changing technical standards of medical care 
(Donabedian, 1997). The definition explicitly states that assessment of quality relies 
exclusively on examining how good a health service is, and the goodness of the 
services is judged by the current relevant professional knowledge. That is, the 
likelihood of good outcomes of medical care increases by applying the current, 
relevant technical knowledge in examining (and improving) health services 
(Pronovost et al., 2004). The current professional knowledge refers to the scientific 
evidence by which the health services are judged.  
The definition is also limited to the technical quality. Two quality 
components have  been identified: technical (the perspective of clinicians), and art 
(human and cultural appropriateness, the patient’s perspective) (Donabedian, 1997). 
Technical quality assessment is the business of clinical sciences while the artistic 
part is the business of social sciences. The technical quality means that the patient 
receives only the procedures, tests, or services for which probability of achieving the 
desired health outcomes exceed the potential risks by a sufficiently wide margin; and 
that each of these procedures or services is performed in a technically excellent 
manner. The art component of quality is determined by the values the patients carry; 
 17
patients would like to be involved in the decision of how the care is offered them 
(Brook et al., 2000). 
2.2.1 Assessing Quality in Medical Care 
There are many frameworks to conceptualize quality in medical care. The 
Donabedian quality assessment framework is widely accepted by clinical professions 
as well as healthcare administration. It conceptualizes three dimensions of quality: 
structure, process and outcome (Donabedian, 1978). Accordingly, healthcare quality 
can be assessed by examining one or more of these dimensions. Under this 
framework, investigation on quality of care is a part of health systems research. The 
European Drug Utilization Research Quality Indicators Meeting (DURQUIM) has 
adopted this framework for quality improvement research (Hoven et al., 2005). 
The structure is the dimension that examines the attributes of settings where 
the care is delivered. Examining the structure deals with many aspects including the 
number of staff and their qualifications, availability of instruments and expertise, 
availability of drug lists, drugs, treatment protocols and treatment guidelines. The 
process is the dimension of quality that deals with how the care is delivered and it 
investigates whether “good” medical practices are followed. Criteria and standards 
are used to examine the process of care. The outcome dimension looks at the impact 
of the care on health status and wellbeing of individuals and community. The 
outcome of healthcare delivery is linked to both the structure and the process. It is 
thought that well-structured facilities provide good outcome of healthcare. It is also 
expected that good process in healthcare delivery results in good outcomes. 
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2.2.1.a Outcome Assessment 
Outcome in healthcare is defined as the “primary changes in health status that 
can be attributed to the care” (Donabedian, 1978). Outcomes assessment can be defined 
as the evaluation of the impact of medical and non-medical interventions, the health 
care process, and the structure of the health care system on clinical, economic, and 
humanistic outcomes, such as patient health-related quality of life and patient 
satisfaction (Gandhi et al., 1999). 
It has always been argued that assessing the outcome of healthcare is the best 
way to judge the quality of delivered care. Some scholars have counter arguments 
that assessing outcome is a valid measure in technology assessment studies such as 
clinical trials but not in quality assessment. Quality assessment is an administrative 
technique that aims to improve quality in real healthcare setting (Donabedian, 1997).  
There are certain situations in which the outcome is not a valid measure of 
quality (Brook et al., 2000). First, there are factors unrelated to the care that have an 
effect on the outcome such as natural history of the disease, patient’s physiologic 
factors and patient’s age. In such instances, the outcome (good or bad) is not merely 
the result of good or bad care. In another word, the specificity is low (Flanagan et al., 
2004, Donabedian, 1997). Second, some outcomes take a lengthy time before they 
manifest. This makes judging the outcome from the care impractical. Furthermore, 
assessing the outcomes misses the opportunity of identifying the pattern of care that 
could be a potential underlying cause of undesired outcomes, if any. All these factors 
represent practical limitations of using the outcomes to assess the quality of medical 
care. 
Another limitation of assessing the outcome as a valid measure of quality is 
that operationalisation of outcomes measures is difficult. In present day healthcare 
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systems, patients’ clinical data as well as administrative data are stored in large 
computerized databases. Standardization of data entry, documentation of events 
related to patient care as well as computer programs are needed for the purpose of 
data retrieval from these databases. Research has shown that data related to the 
clinical outcomes of medical care suffer from unstandardized data entry and poor 
documentation especially in diagnoses coding and results of laboratory tests (Palmer, 
1997, Gandhi et al., 1999, Hammersley et al., 2006, Harpe, 2009, Roth et al., 2009). 
In their computer-assisted detection of preventable rug-related morbidity (PDRM) 
indicators, Hammersley and colleagues (2006) admitted the complexity of the 
queries and the need to detect the temporal relation between pattern of drug use and 
the PDRM. All these represent challenges and difficulties in using these data sources 
to assess the outcome of care, at least in the present time.  
Another factor that can limit using outcome for quality assessment is the 
effect of diagnosis coding in computerized healthcare data. Previous research 
documented the significant role of the coding system on the accuracy of the findings. 
Honigman and colleagues (2001) investigated the effect of the diagnosis coding 
system on the accuracy of detecting adverse drug events (ADEs) in outpatients 
electronic medical records. The International Classification of Diseases (ICD-9-CM) 
system was the poorest in detecting ADEs, where database screening correctly 
identified only five events out of the 248 events identified by chart review (the 
positive predictive value was 2%). The study attributed this low accuracy to two 
reasons. First, the ICD codes of drug injuries (the E codes) were not used by 
physicians in the institution investigated. Second, the non-specific nature of ICD 
codes, which makes it not suitable for ADEs detection.  
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2.2.1.b Process Assessment  
The second way of assessing the quality of care is by examining its process 
dimension. In some instances where measuring the outcome is impractical, not 
possible or unreliable, measuring the process of care offers a valuable alternative. 
Assessing the care process intents to know whether what is considered good 
knowledge has been applied. Examining process for quality assessment has its 
maximal validity when there is good evidence that links the process to the outcomes. 
These links must either have been demonstrated in clinical trials or have widely been 
accepted by professional experts (Mainz, 2003, Pronovost et al., 2004). Care delivery 
concordant with the evidence derived from either of these two sources is called 
evidence-based practice. Another advantage of examining the process is that deficits 
in care delivery are identifiable and possibly correctable (Rubin et al., 2001a). 
Examining the process of care assesses whether providers perform their professional 
tasks in concordance with achieving the desired aims of care and avoid practices that 
predispose patients to harm.  
Assessing the process dimension as a measure of quality of care is acceptable 
to healthcare providers because they feel accountable for the care they deliver (Rubin 
et al., 2001a, Rubin et al., 2001b, Pronovost et al., 2004, Pronovost et al., 2005). In 
the era of electronic medical records (EMR), the process of care can be examined 
retrospectively with reasonable reliability (Palmer, 1997). Among the disadvantages 
of examining the process of care is that criteria and standards for judgment should be 
updated continuously.  
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2.2.1.c Structure Assessment 
The third way of assessing the quality of care is to examine the setting in 
which the care is delivered, i.e. the structure. This approach investigates the 
availability and the adequacy of equipment, protocols and guidelines, staff and their 
qualifications, expertise as well as some managerial structures, operational programs 
and documentation systems. The advantage of this approach is the ease of getting the 
required information for quality assessment. Examining the structure, as a measure of 
quality, relies on the assumption that adequate structure produces good outcomes. 
However, the relationships between the structure and the outcome and between the 
structure and the process are not well established and cannot be guaranteed at all 
times. In their review, Brook and colleagues (2000) argued, referring to examples 
from the literature, against using structure measures alone to assess quality. They 
stated that the relationship between the structure and the process are “weak, 
inconsistent, and paradoxical”.  
2.2.2 Quality Indicators, Criteria and Standards 
To measure quality, regardless of its dimension, we need to define tools by 
which a dimension of quality can be measured. These tools are called indicators. 
Indicators are explicitly defined and measurable items that serve the purpose of 
quality assessment (Campbell et al., 2003). A quality indicator is defined as a 
measurable element of practice performance for which there is evidence or consensus 
that it can be used to assess quality (Lawrence and Olesen, 1997). The European 
working party on quality in primary care (EQuiP) has adopted the previously-
mentione definition of quality indicator (Haaijer-Ruskamp et al., 2004).  
In quality studies, quality indicators are usually applied retrospectively where 
each indicator is presented with numerator and denominator. For example, if the 
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number of post myocardial infarction patients who were prescribed aspirin is the 
numerator, the denominator would be number of patient with myocardial infarction 
without a contraindication to use aspirin. To operationalize quality indicators, criteria 
and standards have to be defined. The following are the definitions of these terms 
according to Campbell and colleagues (2003) with clarifying examples. Unlike 
indicators, criteria assess the care on case-by-case bases. A criterion is a 
systematically developed statement relating to a single medical act, and is so clearly 
defined that it is possible to say whether a good care has been provided. For example, 
if the patient had myocardial infarction event, was aspirin prescribed to him/her? 
While criteria give an answer of “Yes” or “No” on each single case about 
whether a specific care was offered (or a specific outcome was achieved), standards 
set the extent of allowable deviation from the criteria. A standard is defined as the 
level of compliance with the indicator or the criterion. Standards are set according to 
the context in which the care takes place. A target standard is a predetermined level 
of compliance with the criteria (for example, 90% of patients who had myocardial 
infarction should be prescribed aspirin) unless contraindicated. The achieved 
standard is what was found from the indicator study (for example, only 80 % of 
patients who had myocardial infarction were prescribed aspirin provided that they do 
not have contraindication to aspirin). 
After developing quality indicators and defining the standards, these 
parameters are applied to measure the quality. Defects detected are then corrected. 
It should be noted that the way quality indicators are developed depends 
greatly on the way it will be used and on which stakeholders’ (professionals, 
managers, third party payers, patients, carers) perspectives they are intended to 
reflect (Campbell et al., 2002, Campbell et al., 2003). In addition to using them for 
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quality improvement, quality indicators can be used to monitor, reward, penalise, or 
compare care provision. Different stakeholders have different views of quality. Thus, 
when developing indicators to assess quality, these differences have to be taken into 
consideration (Rubin et al., 2001b). Healthcare professionals usually focus on 
professional standards and outcomes of the care they provide. Managers look at 
efficiency, patients’ satisfaction, accessibility of care and outcomes. From the 
patients’ perspective, quality is often related to understanding attitude, 
communication skills, and clinical performance. It is also important to relate the 
quality indicator development to the dimension of care (structure, process or 
outcome) it will assess. The focus here is on the process of care. Process assessment 
has been the object of quality assessment and improvement (Brook et al., 2000).  
2.2.3 Methods of Developing Quality Indicators 
There are three methods for indicator development. The first one is a non-
systematic approach, which does not rely on evidences from the medical literature. It 
is based on the professional experience of developers of indicators. This approach 
offers easy and quick way to develop indicators. This approach is also suitable for 
areas like critical care where patient’s conditions are so complex that it is difficult to 
fit under categories for which evidence exists. A disadvantage to this approach is that 
the level of disagreement between experts can be so high that the reliability and the 
validity of the developed indicator are questionable; hence higher number of 
reviewers is usually required at the time of its application (Rubin et al., 2001b).  
 The second method is a systematic approach. It is based on scientific 
evidence derived from rigorously conducted studies. This approach should be 
adopted in developing indicators whenever possible. The stronger the evidence, the 
more beneficial will the indicator be in quality assessment and improvement 
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